Premarket Mover: Lineage Cell Therapeutics Inc (LCTX) Down 1.77%

Lineage Cell Therapeutics Inc (LCTX) is lower by Monday morning, with the stock losing -1.77% in pre-market trading to 1.11. LCTX's short-term technical score of 58 indicates that the stock has traded more bullishly over the last month than 58% of stocks on the market. In the Biotechnology industry, which ranks 134 out of 146 industries, LCTX ranks higher than 76% of stocks. Lineage Cell Therapeutics Inc has fallen 4.24% over the past month, closing at $1.13 on October 2. During this period of time, the stock fell as low as $1.11 and as high as $1.37. LCTX has an average analyst recommendation of Strong Buy. The company has an average price target of $5.50.

LCTX has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on LCTX!

See Full LCTX Report

Lineage Cell Therapeutics Inc has a Long-Term Technical rank of 31. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 69% of the market scoring higher. In the Biotechnology industry which is number 132 by this metric, LCTX ranks better than 132% of stocks.

Important Dates for Investors in LCTX:

-Lineage Cell Therapeutics Inc is set to release earnings on 2023-11-09. Over the last 12 months, the company has reported EPS of $-0.13. -We do not have a set dividend date for Lineage Cell Therapeutics Inc at this time. Click Here To Get The Full Report on Lineage Cell Therapeutics Inc (LCTX)